Reality not insanity - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Reality not insanity
CDMOs waiting for the pipeline to come roaring back are kidding themselves.

Pharmaceutical Technology Europe
Volume 21, Issue 11

Coming to terms

The contract services industry needs to come to terms with the fact that the new product gravy train is coming to an end. The number of candidates in development is shrinking and the amount spent on them is falling. R&D spending by small bio/pharma companies dropped 20% in the first half of 2009 and the large and midsize companies have also slowed their spending. We may get an upturn in the second half of the year as some delayed programmes are accelerated, but the trend seems pretty clear.

A decline in R&D spending will hurt smaller CROs and CMOs the most because it will be concentrated in the discovery, preclinical and Phase I segments of the pipeline. Those are the segments of the pipeline that will feel the greatest effects of the venture capital pullback, and the venture-backed bio/pharmas are the most dependent on contractors.

Large public CROs and CMOs will also feel the heat. Their stock prices were driven up to record levels during the middecade, as high doubledigit revenue and profit growth rates became the norm. Those growth rates have slowed dramatically and aren't likely to reach their pre2008 levels. The Phase II and Phase III research programmes have been well supported thus far, but the efforts to kill likely failures more quickly will ultimately shrink the latestage pipeline.

Contract services will benefit from the increased willingness of the major bio/pharma companies to outsource more of their development activities. However, much of that benefit will accrue to large CROs and CMOs, and to service providers with operations in the emerging markets. Owners and investors of contract service providers must come to terms with this new reality. The venture capitalists and executives of the major bio/pharma companies are not insane; they have already turned away from the practices that fuelled the great pipeline explosion this decade. CROs and CMOs will now need to find other ways to fuel their growth.

Jim Miller is President of PharmSource and a member of Pharmaceutical Technology Europe's Editorial Advisory Board.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology Europe,
Click here